| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SEMA6A |
| Uniprot No | Q9H2E6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-649aa |
| 氨基酸序列 | MRSEALLLYF TLLHFAGAGF PEDSEPISIS HGNYTKQYPV FVGHKPGRNT TQRHRLDIQM IMIMNGTLYI AARDHIYTVD IDTSHTEEIY CSKKLTWKSR QADVDTCRMK GKHKDECHNF IKVLLKKNDD ALFVCGTNAF NPSCRNYKMD TLEPFGDEFS GMARCPYDAK HANVALFADG KLYSATVTDF LAIDAVIYRS LGESPTLRTV KHDSKWLKEP YFVQAVDYGD YIYFFFREIA VEYNTMGKVV FPRVAQVCKN DMGGSQRVLE KQWTSFLKAR LNCSVPGDSH FYFNILQAVT DVIRINGRDV VLATFSTPYN SIPGSAVCAY DMLDIASVFT GRFKEQKSPD STWTPVPDER VPKPRPGCCA GSSSLERYAT SNEFPDDTLN FIKTHPLMDE AVPSIFNRPW FLRTMVRYRL TKIAVDTAAG PYQNHTVVFL GSEKGIILKF LARIGNSGFL NDSLFLEEMS VYNSEKCSYD GVEDKRIMGM QLDRASSSLY VAFSTCVIKV PLGRCERYGK CKKTCIASRD PYCGWIKEGG ACSHLSPNSR LTFEQDIERG NTDGLGDCHN SFVALNGHSS SLLPSTTTSD STAQEGYESR GGMLDWKHLL DSPDSTDPLG AVSSHNHQDK KGVIRESYLK GHDQLVPVT |
| 预测分子量 | 72 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural Basis of Semaphorin-6A Guidance Receptor Activity"** by Antipov, Y. et al.
摘要：解析SEMA6A胞外结构域重组蛋白的晶体结构，揭示其二聚化机制及与Plexin-A4受体的相互作用模式，阐明轴突导向的分子基础。
2. **"Sema6A regulates axon guidance via Plexin-A4 interaction in the developing nervous system"** by Haklai-Topper, L. et al.
摘要：通过重组SEMA6A蛋白体外实验，证明其通过结合Plexin-A4抑制神经元轴突生长，提示其在神经环路形成中的关键作用。
3. **"SEMA6A promotes tumor progression in colorectal cancer by enhancing EMT signaling"** by Wang, Q. et al.
摘要：利用重组SEMA6A蛋白处理癌细胞，发现其通过激活上皮-间质转化(EMT)通路促进肿瘤细胞迁移和侵袭，提示其作为癌症治疗靶点潜力。
4. **"Sema6A reverse signaling mediates oligodendrocyte myelination"**由 Toyofuku, T. et al.
摘要：通过重组SEMA6A胞内结构域蛋白实验，揭示其反向信号传导促进少突胶质细胞髓鞘形成，为脱髓鞘疾病研究提供新方向。
**Background of SEMA6A Recombinant Protein**
Semaphorin 6A (SEMA6A) is a member of the semaphorin family, a group of membrane-associated or secreted proteins initially identified as axon guidance molecules during neural development. SEMA6A is a transmembrane protein characterized by a conserved ~500-amino acid Sema domain, followed by a plexin-semaphorin-integrin (PSI) domain and a cytoplasmic tail. Unlike many semaphorins, SEMA6A primarily functions as a receptor or co-receptor through interactions with plexin receptors, mediating bidirectional signaling critical for cell-cell communication, cytoskeletal reorganization, and tissue morphogenesis.
SEMA6A plays diverse roles in physiological and pathological processes. In the nervous system, it regulates axon guidance, neuronal migration, and synapse formation. Beyond neurobiology, SEMA6A is implicated in vascular development, immune modulation, and cancer progression. For instance, it influences tumor angiogenesis, metastasis, and the tumor microenvironment by modulating cell adhesion, motility, and signaling pathways such as MAPK and Rho GTPases. Dysregulation of SEMA6A has been linked to neurodevelopmental disorders, cardiovascular diseases, and malignancies.
Recombinant SEMA6A protein, typically produced in mammalian expression systems (e.g., HEK293 cells), retains the functional extracellular domain required for ligand-receptor interactions. It is purified and often tagged (e.g., Fc or His tags) for experimental applications. This protein serves as a vital tool to study SEMA6A-mediated signaling *in vitro* or *in vivo*, including receptor binding assays, cell migration studies, and mechanistic investigations into its role in diseases. Additionally, recombinant SEMA6A is explored for therapeutic potential, such as blocking aberrant signaling in cancer or promoting neural repair.
Research on SEMA6A continues to uncover its context-dependent roles, emphasizing its dual functions as a tumor suppressor or promoter, depending on cellular milieu. Its recombinant form thus bridges fundamental research and translational applications in biomedicine.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
